American Thoracic Society (ATS) 2022

Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial

Acute exacerbations in patients with progressive fibrosing interstitial lung diseases: data from the INBUILD trial

Real-world medication adherence trajectories of nintedanib among idiopathic pulmonary fibrosis patients

Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis

Incidence of progressive phenotype in fibrosing interstitial lung disease (PF-ILD) in a tertiary healthcare center

Phosphodiesterase inhibition as a novel strategy to stop fibrosis in the lung